| Name | Title | Contact Details |
|---|
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.
Company ProfileVerisante Technology, Inc (Formerly T-Ray Science) is a medical device company committed to developing innovative systems for the early detection of cancer.
CareLink Community Services provides a progressive approach to rehabilitation, wellness, & autonomy for people with disabilities.
Prescription Solutions is an innovative pharmacy benefit management company managing the prescription drug benefit of commercial, Medicare and other governmental health plans, as well as those of employers and unions. A UnitedHealth Group company,
Novacea, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.